Structure Therapeutics (GPCR) Other Non-Current Liabilities (2023 - 2026)
Structure Therapeutics (GPCR) posted quarterly Other Non-Current Liabilities of $863000.0 for Q1 2026, up 180.19% year-over-year from $308000.0 in Q1 2025, and up 33.38% quarter-over-quarter from $647000.0 in Q4 2025.
Structure Therapeutics (GPCR) Other Non-Current Liabilities (2023 - 2026) Analysis & Trends
Structure Therapeutics' Other Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $863000.0 for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 180.19% year-over-year to $863000.0; the TTM figure through Mar 2026 stood at $863000.0 (up 180.19% YoY), while the FY2025 annual figure was $647000.0, up 114.24% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $863000.0, up from $647000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $863000.0 in Q1 2026, with the low at $281000.0 in Q3 2023.
- The 4-year median for Other Non-Current Liabilities is $308500.0 (2024), against an average of $394600.0.
- The sharpest annual moves came in 2024 and 2026: Other Non-Current Liabilities rose 1.34% in 2024, then soared 180.19% in 2026.
- Structure Therapeutics' Other Non-Current Liabilities stood at $298000.0 in 2023, then gained by 1.34% to $302000.0 in 2024, then soared by 114.24% to $647000.0 in 2025, then surged by 33.38% to $863000.0 in 2026.
- Business Quant data shows GPCR's Other Non-Current Liabilities at $863000.0 in Q1 2026, $647000.0 in Q4 2025, and $325000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Structure Therapeutics | 11.65 Bn | 11.65 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.27 Mn |
| Mar 31, 2026 | 863,000.00 |
| Dec 31, 2025 | 647,000.00 |
| Sep 30, 2025 | 325,000.00 |
| Jun 30, 2025 | 317,000.00 |
| Mar 31, 2025 | 308,000.00 |
| Dec 31, 2024 | 302,000.00 |
| Sep 30, 2024 | 309,000.00 |
| Mar 31, 2024 | 296,000.00 |
| Dec 31, 2023 | 298,000.00 |
| Sep 30, 2023 | 281,000.00 |